Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) FCF Margin (2016 - 2025)

Historic FCF Margin for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to 11.32%.

  • Ligand Pharmaceuticals' FCF Margin fell 591800.0% to 11.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.65%, marking a year-over-year increase of 408500.0%. This contributed to the annual value of 56.98% for FY2024, which is 219000.0% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' FCF Margin stood at 11.32%, which was down 591800.0% from 32.72% recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' FCF Margin peaked at 237.43% during Q4 2024, and registered a low of 148.28% during Q2 2024.
  • Moreover, its 5-year median value for FCF Margin was 27.29% (2022), whereas its average is 37.43%.
  • The largest annual percentage gain for Ligand Pharmaceuticals' FCF Margin in the last 5 years was 2102200bps (2024), contrasted with its biggest fall of -1472000bps (2024).
  • Over the past 5 years, Ligand Pharmaceuticals' FCF Margin (Quarter) stood at 45.12% in 2021, then surged by 126bps to 101.9% in 2022, then tumbled by -73bps to 27.22% in 2023, then soared by 772bps to 237.43% in 2024, then tumbled by -95bps to 11.32% in 2025.
  • Its FCF Margin stands at 11.32% for Q3 2025, versus 32.72% for Q2 2025 and 56.6% for Q1 2025.